First Tracks Biotherapeutics (TRAX) Stock Insights

TRAX price $45.72 +0.34 +0.75%

Ticker
TRAX
Price
$45.72
Change
+0.34 +0.75%
Market cap ?
$1.64B
P/E ?
-12.57
Dividend yield ?
0.00%
Beta ?
3.37
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
61
Value
34
Quality
52
Growth
98

Stocklytics score rationale: value 34, quality 52, growth 98.

Financials

202320242025
000

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Fair value

TRAX fair value Not meaningful. Price $45.72.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare TRAX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-11—-0.92——
2026-08-12-0.95-0.80—75.00M
2026-05-14-1.45-0.98—22.26M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-15Orwin John ABuy1.30K——
2026-09-15Orwin John ASell1.30K——
2026-09-02Ware J. AnthonyBuy39.27K$5.74225.38K
2026-09-02Ware J. AnthonySell39.27K$44.781.76M
2026-09-02Ware J. AnthonySell28.57K$5.74164.00K
2026-09-02Ware J. AnthonySell10.69K$5.7461.38K
2026-08-15STONE BENJAMINBuy60.49K——
2026-08-15Lizzul Paul F.Buy60.49K——
2026-08-15Faga DanielBuy193.57K——
2026-08-02STONE BENJAMINBuy60.49K——
2026-08-02Lizzul Paul F.Buy60.49K——
2026-08-02Faga DanielBuy193.58K——
2026-04-20Lizzul Paul F.Other16.67K——
2026-04-20STONE BENJAMINOther16.67K——
2026-04-20Faga DanielOther53.33K——
2026-04-20ANAPTYSBIO, INCSell100——
2026-04-01ANAPTYSBIO, INCOther0——

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 153. Ownership 98.85%.

HolderSharesChangeChange %Value
ECOR1 CAPITAL, LLC3.17MNewNew63.87M
TCG CROSSOVER MANAGEMENT, LLC2.90MNewNew58.25M
FMR LLC2.05MNewNew41.33M
AFFINITY ASSET ADVISORS, LLC2.03MNewNew40.88M
BLACKROCK, INC.1.96MNewNew39.51M
TRAILS EDGE CAPITAL PARTNERS, LP1.51MNewNew30.46M
STATE STREET CORP1.51MNewNew30.44M
VANGUARD CAPITAL MANAGEMENT LLC1.45MNewNew29.21M
JUPITER TOPCO LLC1.09MNewNew21.96M
VESTAL POINT CAPITAL, LP1.01MNewNew20.38M
WOODLINE PARTNERS LP917.18KNewNew18.45M
SANOFI821.92KNewNew16.54M
MORGAN STANLEY781.53KNewNew15.72M
683 CAPITAL MANAGEMENT, LLC750.00KNewNew15.09M
ADAGE CAPITAL PARTNERS GP, L.L.C.729.00KNewNew14.67M
BALYASNY ASSET MANAGEMENT L.P.714.95KNewNew14.38M
GEODE CAPITAL MANAGEMENT, LLC702.09KNewNew14.13M
BANK OF AMERICA CORP /DE/647.96KNewNew13.04M
STEMPOINT CAPITAL LP622.72KNewNew12.53M
PALO ALTO INVESTORS LP603.49KNewNew12.14M
SOFINNOVA INVESTMENTS, INC.565.20KNewNew11.37M
VANGUARD PORTFOLIO MANAGEMENT LLC546.99KNewNew11.01M
GOLDMAN SACHS GROUP INC487.21KNewNew9.80M
POINT72 ASSET MANAGEMENT, L.P.408.33KNewNew8.22M
UBS GROUP AG310.89KNewNew6.26M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

First Tracks Biotherapeutics (TRAX) Stock Insights

TRAX$45.72+0.34 +0.75%

$1.64B

Market Cap

-12.57

P/E

—

Forward P/E

61

Score

Price History